US Peptide CDMO Capacity and Demand: A Mid-2026 Market Assessment

US peptide CDMO capacity is running at 78-85% utilization across established manufacturers in mid-2026, approaching the threshold where demand-driven delays begin affecting clinical program timelines. New capacity additions, primarily from expansion projects announced in 2022-2024, are coming online through 2026-2027, but the near-term gap is real and affecting programs in the Phase 1-2 range most severely.

The US Peptide CDMO Market Structure

The US contract development and manufacturing market for synthetic peptides is served by a tiered set of organizations:

Tier 1: Large integrated CDMOs with full-service capability from process development through commercial manufacturing. Organizations including PolyPeptide Group's US operations, Bachem Americas, Piramal Pharma Solutions' peptide division, and Almac Group's US facility represent this tier. These organizations can support programs from kilogram-scale clinical supply through multi-ton commercial manufacturing and offer comprehensive QA/QC, regulatory support, and formulation capabilities.

Tier 2: Mid-size specialty CDMOs focused on specific peptide capabilities, complex synthetic modifications, conjugate synthesis, or particular therapeutic area expertise. These organizations typically support clinical-stage programs through Phase 2-3 and may not have commercial manufacturing capacity.

Tier 3: Small-scale CROs with synthesis capabilities providing discovery and preclinical quantities, often with academic collaborations. These organizations are not regulated for GMP clinical supply but serve the early pipeline.

The US market is distinguished from European and Asian alternatives primarily by proximity (advantageous for regulatory interactions and supply chain risk management), FDA familiarity (preferred by US-based sponsors for their first GMP manufacturing partner), and specialized technical capabilities in areas like complex cyclic peptide synthesis and high-potency compound handling.

Current Capacity Utilization Assessment

Available capacity data from CRO/CDMO industry surveys and interviews with procurement professionals at mid-size pharmaceutical and biotech companies suggests the following utilization picture for Q2 2026:

Phase 1 clinical supply capacity: Estimated 82% average utilization at Tier 1 CDMOs. Lead times for new program starts have extended to 9-15 months from contract execution, up from 6-9 months in 2023. Phase 1 supply bottlenecks are most acute for programs requiring:

• Novel cyclic or stapled peptide synthesis not in the CDMO's standard capability portfolio
• GMP manufacture of peptide-lipid conjugates (Tier 1 CDMOs with this capability are at or near full utilization)
• Rapid turnaround for accelerated development programs

Phase 2-3 clinical supply capacity: Estimated 78% average utilization at Tier 1 CDMOs with appropriate scale capability. This segment is experiencing the most rapid demand growth as GLP-1 competitor programs, antimicrobial peptide programs, and cancer vaccine programs all advance toward pivotal trials simultaneously.

Commercial manufacturing capacity: Tight for programs entering commercial manufacturing, with 12-18 month lead times for initiating technology transfer processes. Several sponsors of late-stage programs have begun dual qualification of US and European CDMOs to reduce commercial supply risk, further increasing overall capacity demand.

Capacity Additions Underway

Several significant capacity additions are in process or recently completed:

PolyPeptide Group facility expansion in San Diego has added kilogram-scale SPPS capacity with specialized capabilities for complex peptide conjugates. The expansion brings approximately 30% additional Phase 1-2 clinical supply capacity online in 2026.

Bachem's expansion of its US manufacturing infrastructure in Torrance, California, has increased GMP synthesis capacity and added dedicated cyclic peptide synthesis capabilities. Bachem has publicly committed to significant US capacity investment through 2027 to address demand from the GLP-1 pipeline and oncology peptide programs.

Multiple second-tier CDMO expansions focusing on specific capability gaps: lipid-conjugated peptide synthesis, high-potency compound handling, and personalized peptide vaccine manufacturing are the primary technical areas attracting new facility investment.

Despite these additions, capacity analysts project that the US peptide CDMO market will remain capacity-constrained through 2026-2027, with supply tightening rather than loosening as demand from Phase 3 and commercial-stage programs grows faster than new capacity comes online.

Demand Drivers Through 2027

The programs most significantly driving capacity demand through the forecast period:

GLP-1 competitive programs: Estimated 40+ active clinical programs for GLP-1 receptor agonists and dual/triple agonist peptide drugs are competing simultaneously for SPPS synthesis capacity. Many of these programs require large quantities (hundreds of kilograms) for Phase 3 trials and are entering the clinical pipeline at the same time.

Cancer neoantigen vaccine programs: Personalized cancer vaccine manufacturing represents an entirely new capacity demand category, manufacturing dozens of unique GMP peptide batches for each patient. As programs from Neon/BMS and academic medical center collaborators scale up, the demand for small-scale, rapid-turnaround GMP peptide synthesis is generating capacity requirements unlike traditional pharmaceutical manufacturing.

Antimicrobial peptide programs: Multiple AMP programs have advanced to Phase 2-3 and require larger quantity clinical supply for efficacy trials. The structural complexity of many clinical AMP candidates (cyclic, branched, or lipidated) limits the number of CDMOs capable of supporting them.

Pricing Environment

Capacity tightness is supporting CDMO pricing power. Industry data suggests:

• Process development fees at Tier 1 US CDMOs have increased 15-25% over 2023 benchmarks
• GMP synthesis costs per gram have increased 10-20% for programs at the Phase 1-2 scale
• Long-term supply agreements for commercial manufacturing are being negotiated at pricing levels reflecting tighter supply, sponsors are accepting higher per-unit costs in exchange for supply security

For biotech companies managing peptide program budgets, the capacity tightness environment means that early engagement with CDMO partners, often 12-18 months before GMP synthesis is needed, is now a best practice rather than an aspiration. Organizations that wait for an IND to be filed before initiating CDMO evaluation risk encountering unavailable capacity at the required scale and chemistry.

Strategic Implications for Sponsors

For pharmaceutical and biotech companies managing peptide programs:

• Start CDMO evaluation at or before Phase 1 IND filing, not after. The lead time for GMP synthesis slot allocation has extended to the point where post-IND CDMO sourcing creates genuine program timeline risk.
• Consider dual-CDMO strategies for Phase 3 and commercial programs, particularly for complex chemistries where a single CDMO failure would create an unrecoverable supply disruption.
• Build direct relationships with CDMO business development teams rather than working exclusively through fee-for-service bid processes, relationship equity is increasingly important for access to constrained capacity in a seller's market.
• Assess non-US CDMO options (European and Indian CDMOs with US facility qualifications) as alternatives to US-only sourcing when US capacity constraints are project-limiting.